Former Biogen executive Michael Ehlers built Intergalactic with a vision to create a different type of gene therapy that wouldn’t need viruses as delivery systems. His team believed they could instead use electroporation, a method that uses electrical fields to open a path for DNA to enter cells.
The company’s website describes its work as “expanding the universe of gene therapy.” And even as the startup closed up shop, Shea said in Intergalactic’s statement that the company’s “platform and programs have shown promise.”
